Team

David served as Chairman of Norfolk and Norwich University Hospitals NHS Foundation Trust from 2002-2012 before becoming Chairman of the Care Quality Commission. In December 2016, he was appointed as Parliamentary Under Secretary of State at the Department of Business, Energy & Industrial Strategy, with specific responsibility for developing industrial strategy. He stepped down from this role in October 2017 to become Chairman of University College London Hospitals and subsequently became Chairman of NHS England and a member of the UK Life Sciences Council from November 2018 to March 2022. He continues to advise the government on Life Sciences and is an advisor to Healthcare UK, providing strategic input into the Department of International Trade's healthcare international exports work.

Rupert Lywood is an original founder of Origin Sciences and provided the company’s early finance. A chartered accountant with specialities in structured finance and venture capital, he has spent the past 25 years founding and building businesses in the energy, information, finance, medical and media sectors. As a key early backer, Rupert’s support was instrumental in establishing Origin Sciences, and he remains actively involved in guiding its growth.

Hugo is passionate about discovery, innovation and commercial conversion. He has worked in a diverse range of fields including scientific education (retail), healthcare (delivery), property (enviro-friendly and affordable), hospitality and latterly primary care investigative and diagnostic solutions (ongoing). Hugo is also the original designer of the OriCol™ device.

Shane Hall FCA, qualified with BDO, before going on to lead the BDO Corporate Finance division in Northern Ireland along with a 20 year professional services career. In this role he became a key advisor to many of Ireland's leading businesses, across a spectrum of sectors, including Biotech (covering private, listed and private equity backed ownerships). His specialisms also include Equity Fund raises, M&A, Due diligence, Debt Advisory and Finanial Modelling.

Lee, a mathematician by training, qualified as a chartered accountant in 2006 and became a partner in 2008, later leading the sale of his firm to Crowe in 2011. He joined Wilson Wright in 2012, advising leading UK entrepreneurs and family offices. In 2015, while remaining a senior partner, he co-founded Polymateria, now a global leader in biodegradable polyolefin plastics. Since then, he has founded and invested in several businesses. In 2024, Lee led the merger of Wilson Wright and BKL into a top-30 UK accountancy firm with PE backing from CBPE. Today, he invests alongside long-term family office partners, helping portfolio companies achieve their full potential.

Hugo is passionate about discovery, innovation and commercial conversion. He has worked in a diverse range of fields including scientific education (retail), healthcare (delivery), property (enviro-friendly and affordable), hospitality and latterly primary care investigative and diagnostic solutions (ongoing). Hugo is also the original designer of the OriCol™ device.

Daniel is an Immunologist by training, with expertise in adaptive immunity, nonself recognition and immuno-oncology. He holds a PhD from the University of Cambridge and was a Fellow at the Technical University of Munich. Daniel has over 10 years research/management experience in; Immunology, cell biology, drug discovery and diagnostics in academia, small bio-tech and big pharma. Most recently, he has led the development of epigenetic screening tools in the diagnostic industry.

Professor Andrew Page is Chief Technical Officer at Origin Sciences and Biomii Health, where he leads bioinformatics and genomics for cancer diagnostics and consumer health testing. He previously held senior roles at Theiagen Genomics, the Quadram Institute, and the Wellcome Sanger Institute. He holds a PhD in Computer Science from the National University of Ireland, Maynooth, and is a Visiting Professor at the University of East Anglia. Andrew is widely recognised for his open-source contributions in microbial bioinformatics.

Ian Daniels is a Consultant Colorectal & General Surgeon based at the Royal Devon & Exeter Hospital. His research interests include the diagnosis and management of bowel cancer, surgery for locally advanced and recurrent bowel cancer. His research portfolio can be viewed on PubMed [Daniels I]. Outside of clinical work he is Honorary President of Colostomy UK.

Shane Hall FCA, qualified with BDO, before going on to lead the BDO Corporate Finance division in Northern Ireland along with a 20 year professional services career. In this role he became a key advisor to many of Ireland's leading businesses, across a spectrum of sectors, including Biotech (covering private, listed and private equity backed ownerships). His specialisms also include Equity Fund raises, M&A, Due diligence, Debt Advisory and Finanial Modelling.

Kiran has worked within the In-vitro Diagnostics industry for over 13 years covering various departments including Manufacturing, Technical Process Development, Technical Services, Quality, and Regulatory. Kiran has extensive experience in Regulatory when it comes to IVD product registrations, technical documentation, layperson (IVDD) CE certification, risk management, and post-market surveillance, ss well as building and managing Quality Management Systems to ISO 13485 and ISO 15189.

Chris is a Chartered Quality Professional (CQP MCQI), with experience gained throughout various industries. Originally qualified as a Mechanical Engineer, working in Manufacturing and Design, Chris later moved into the Quality Assurance sector working within the Medical Device industry. Chris has worked within Quality for over 20 years, working with reputable organisations such as Astra Zeneca, Vectura, Oval Medical and many more. Specialities include ISO 13485, ISO 14971 and Creation and Management of Electronic Quality Management Systems.

Megan is a seasoned professional in medical devices, pharmaceuticals and Diagnostics. Megan has played pivotal roles in device certification and development for startups in regulated fields. With a passion for women's health innovation combined with experience in the venture capital and startup ecosystems, Megan has driven her role of Chief Operating Officer for Origin Sciences, into a new focus for Ellele Health.

Archie has extensive experience in the start-up ecosystem and has played a key role in commercial strategy and fundraising. He previously led commercial strategy and operations at TypeDB, an AI database company. Throughout his career, Archie has been closely involved in building and scaling start-ups, and is now focused on advancing science-led personal health innovation through Biomii Health.

David served as Chairman of Norfolk and Norwich University Hospitals NHS Foundation Trust from 2002-2012 before becoming Chairman of the Care Quality Commission. In December 2016, he was appointed as Parliamentary Under Secretary of State at the Department of Business, Energy & Industrial Strategy, with specific responsibility for developing industrial strategy. He stepped down from this role in October 2017 to become Chairman of University College London Hospitals and subsequently became Chairman of NHS England and a member of the UK Life Sciences Council from November 2018 to March 2022. He continues to advise the government on Life Sciences and is an advisor to Healthcare UK, providing strategic input into the Department of International Trade's healthcare international exports work.

Mike is a British oncologist with more than 25 years' experience as a hospital physician. From 1999 to 2013 Mike was appointed as the first National Cancer Director at the Department of Health. He led the development and implementation of the NHS Cancer Plan in 2000, the Cancer Reform Strategy in 2008 and Improving Outcomes: A strategy for cancer in 2011. Sir Mike led two major reviews for NHS England. A review of adult screening services (2019) and a review of diagnostic services (2020) recommending a major expansion of diagnostic capacity and a new model of service delivery. He is currently working with NHS England to help implement his report and is a trustee of Cancer Research UK. In April 2022 he was appointed as Chair of the UK National Screening Committee. In 2024 he conducted a review of the Single Assessment Framework and its implementation for CQC, which he has since been appointed as its Chair.

Bruce Campbell chaired the NICE Interventional Procedures and Medical Technologies Advisory Committees - 2002-15 and 2009-15 respectively; and he chaired the Therapeutic Procedures Panel of the Health Technology Assessment Programme 2000-8. He was a Non-Executive Director of the MHRA 2015-21. He is a vascular consultant in Exeter and has published extensively on clinical topics, and on health technology assessment.

A Professor of Biomedical Materials and Regenerative Medicine, and the Research Director for Biomedical Sciences in the Institute of Biomedical Sciences in the Institute of Biomedical Engineering at Imperial College. Recognised by The Times as one of the top ten scientists, she has also recently been recognised by the TR100.